DocumentsDate added
Research article
Wisam R. Hassan1,*,Haydar F. AL-Tukmagi1,Osamah T. Muslim2
Affiliation:-
1Department of Clinical Pharmacy, College of Pharmacy, University of Baghdad, Baghdad, Iraq
2Department of Gastroenterology and Hepatology ,AL-Diwaniya Teaching Hospital, College of Medicine, University of AL-Qadisyia, AL-Qadisyia, Iraq
The name of the department(s) and institution(s) to which the work should be attributed:
1.Department of Clinical Pharmacy, College of Pharmacy, University of Baghdad, Baghdad, Iraq
2.Department of Gastroenterology and Hepatology,AL-Diwaniya Teaching Hospital, College of Medicine, University of AL-Qadisyia, AL-Qadisyia, Iraq
Address reprint requests to
Wisam R. Hassan.
Department of Clinical Pharmacy, College of Pharmacy, University of Baghdad, Baghdad, Iraq
Article citation:
Hassan WR, Al-Tukmagi HF, Muslim OT. Efficacy of a 10 Days course of levofloxacin based therapy after Failure of sequential therapy for Helicobacter pylori infection in Iraqi Patients. J Pharm Biomed Sci. 2014; 04(11):1031-1038. Available at www.jpbms.info
ABSTRACT
Helicobacter pylori (H. Pylori) is one of the most important risk factors of Peptic ulcer disease (PUD) and gastric cancer. The success rate of triple therapy (TT) has been declined during the last decade , sequential therapy (ST)has been proposed as an alternative to the TT regimen. A 10 days levofloxacin-based therapy(LBT) constitutes an encouraging second-line strategy after failure of ST.
The aim of this study was to establish the efficacy and tolerability of LBT after failure of (ST), also measuring the cumulative eradication rate of both regimens.
A prospective, open-label randomized clinical trial on 86 patients who had active H. Pylori infection with various gastrointestinal symptoms. The second line LBT was given after failure of the first line ST, bacterial eradication was examined 4-8weeks after treatment by using a fecal antigen test (FAT). The result was 20 patients after ST failure, only 19 patients enrolled to take LBT. The eradication rate(ER) of per-protocol and intention-to-treat for second line was 84.21% (16/19, 95% C.I 68%-100.1%) for both genders without significant difference (p=0.76) between males and females, cumulative eradication rates were 94.86% and 95.95% for both intention-to-treat and per-protocol, respectively. Compliance to the second line was 100% and adverse effects were mostly mild (36.84%) to moderate (10.56%), with little sever (5.26%) that had no effect on completion of treatment. It is concluded that a 10 days levofloxacin based therapy constitutes an encouraging second line regimen after failure of sequential therapy, with a high compliance and low adverse effects and yield a high cumulative eradication rate in clinical practice.
KEYWORDS: H. Pylori; levofloxacin; sequential therapy.
REFERENCES
1.Del Valle J et al. Acid peptic disorders. In: Yamada T et al., eds. Textbook of Gastroenterology. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2003:1321-1376.
2.Marshall BJ, Royce H, Annear DI, et al. Original isolation of Campylobacter pyloridis from human gastric mucosa. Microbios Lett 1984; 25: 83-88.
3.Warren, J. R. and Marshall B. J. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet 1983; 1:1273-1275.
4.Marshall, B. J. and Warren J. R. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1984;1:1311-1315.
5.Washington MK, Peek, RM. Gastritis and Gastropathy. In: Yamada T, Alpers DH, Kalloo KN ,et al. eds. Textbook of Gastroenterology,5thed. Hoboken,NJ:Wiley-Blackwell;2009:1005-1025.
6.Costa AC, Figueiredo C, and Touati E. pathogenesis of Helicobacter pylori infection. Helicobacter 2009;14(suppl 1):15-20.
7.Hunt R.H., Chair S.D. Xiao F. Megraud . et al. Helicobacter Pylori in Developing Countries. World Gastroenterology Organization Global Guideline. J Gastrointestinal Liver Dis. September 2011; Vol. 20 No 3, 299-304.
8.Azevedo NF, Huntington J, Goodman KJ. The epidemiology of Helicobacter Pylori and public health implications. Helicobacter 2009;14(suppl. 1):1-7.
9.Talley NJ, Fock KM, Moayyedi P. Gastric cancer consensus conference recommends Helicobacter screening and treatment in a symptomatic persons from high risk population to prevent gastric cancer .Am J Gastroenterology 2008;103:510-514.
10.Leung WK, Ng EKW, Sung JJY. Tumors of the stomach .In: Yamada T, Alpers DH, Kalloo KN, et al . eds. Textbook of Gastroenterology ,5thed. Hoboken, NJ: Wiley –Blackwell;2009:1026-1053.
11.Soll AH, Graham DY. Peptic ulcer disease. In: Yamada T, Alpers DH, Kalloo KN, et al.eds. Textbook of Gastroenterology, 5th ed. Hoboken,NJ:Wiley-Blackwell;2009:936-981.
12.De Francesco V, Giorgio F, Hassan C, et al. Worldwide H. pylori antibiotic resistance: a systematic review. J Gastrointestin Liver Dis. 2010; 19(4):409-414.
13.Saad R, Chey WD. A clinician’s guide to managing Helicobacter pylori infection. Cleve Clin J Med. 2005; Vol. 72, pp.109–118.
14.Zullo A, Rinaldi V, Winn S, et al. A new highly effective short-term therapy schedule for Helicobacter pylori eradication. Aliment Pharmacol Ther 2000;14:715-8.
15.Riccardo U., Rossella C., and Maria E. R. Update on triple therapy for eradication of Helicobacter pylori: current status of the art. Clin Exp Gastroenterol. 2012; 5: 151–157.
16.Gisbert JP, Molina-Infante J, Marin AC et al. Second-line rescue triple therapy with levofloxacin after failure of non-bismuth quadruple "sequential" or "concomitant" treatment to eradicate H. pylori infection. Scand J Gastroenterol. 2013 Jun;48(6):652-6.
17.Smith, SI et al . The use of Helicobacter pylori stool antigen test for the diagnosis of Helicobacter pylori in Lagos, Nigeria. West Indian med. j., Mona.2011;60(1).
18.Evans LT, Saberi S, Kim HM, et al. Pharyngeal anaesthesia during sedated EGDs: is ‘‘the spray’’ beneficial? A meta-analysis and systematic review. Gastrointest Endosc 2006;63:761-6.
19.Antoniades N, Worsnop C. Topical lidocaine through the bronchoscope reduces cough rate during bronchoscopy. Respirology. 2009;14:873-876.
20.Christe C, Janssens JP, Armenian B, et al. Midazolam sedation for upper gastrointestinal endoscopy in older persons: a randomized, double-blind, placebo-controlled study. J Am Geriatr Soc. 2000;48:1398-1403.
21.MacFaddin, Jean F-Biochemical tests for identification of medical bacteria / Jean F. Macfaddin1980; 424.
22.U.S. Department of Health and Human SERVICES (Dethesda, MD., USA) publication Biosafety in Microbiological and Biochemical Laboratories, 1999, 4th ed. (CDC/NIH) and No. (CDC) 88-8395 on reports of laboratory safety procedures on different diseases.
23.Tong JL, Ran ZH, Shen J, Xiao SD. Sequential therapy vs. standard triple therapies for Helicobacter pylori infection: ameta-analysis. J Clin Pharm Ther 2009;34:41—53.
24.Manfredi M, Bazzarri B, &de’Angelis GL. Helicobacter pylori infection: sequential therapy followed by levofloxacin-containing triple therapy provides a good cumulative eradication rate. Helicobacter 2012; 17: 246-253.
25.Calvet X , Lario S, Ramirez- Lazaro MJ. et al. Accuracy of monoclonal stool test of determining cure of H. Pylori infection after treatment. Helicobacter 2010; 15(3):201-205.
26.Biniam M., Beyene M. and Mulat D. Seroprevalence and trend of H. Pylori infection in Gondar University Hospital among dyspeptic patients, Gondar, North West Ethiopia. BMC Research Notes. 2013, 6:346 .
27.Hadeer S. A., Sanaa J. H. and Rayadh A. Z. Prevalence of Helicobacter Pylori Infection in Adult Patients with Dyspepsia in Gastrointestinal and Hepatology Teaching Hospital, Baghdad. world family medicine journal , August 2014; volume 12,issue 6.
28.Mustapha S, Pindiga U, Yusuph H, et al.. Helicobacter Pylori Infection Among Dyspeptic Patients At A Tertiary Hospital In Northern Nigeria. The Internet Journal of Infectious Diseases. 2010 Volume 9 Number 2.
29-Veronica O., Giovanni B., Maria E. A., et al., Impact of Lactobacillus reuteri Supplementation on Anti-Helicobacter pylori Levofloxacin-Based Second-Line Therapy,” Gastroenterology Research and Practice. 2012; 2012:6.
30- Zullo A., De Francesco V., Hassan C., et al. Second-line treatment for Helicobacter pylori eradication after sequential therapy failure: a pilot study, Therapy 2006; 3(2):251–254.
31-Cui Rongli and Zhou Liya. Helicobacter pylori infection: an overview in 2013, focus on therapy. Chinese Medical Journal. 2014; 127(3):568-573.
32-O’Connor A, Gisbert J, O'morain C. Treatment of Helicobacter Pylori infection. Helicobacter 2009;14(suppl 1):46-51.
33-Carothers J.J., Bruce M.G., Hennessy T.W., Bensler M., Morris J.M., Reasonover A.L. et al. The relationship between previous fluoroquinolone use and levofloxacin resistance in Helicobacter pylori infection. Clin Infect Dis 2007; 44:e5-8.
34.Cattoir V., Nectoux J., Lascols C, Deforges L., Delchier J.C., Megraud F. et al. Update on fluoroquinolone resistance in Helicobacter pylori: new mutations leading to resistance and first description of a gyra polymorphism associated with hyper-susceptibility. Int J Antimicrob Agents. 2007;29:389–396.
35. Zullo A., de Francesco V., Manes G., Scaccianoce G., Cristofari F., and Hassan C., “Second-line and rescue therapies for Helicobacter pylori eradication in clinical practice,” Journal of Gastrointestinal and Liver Diseases, 2010;19(2):131–134.
36.Gisbert J, Marcos S, Moreno-Otero R, Pajares J. Third-line rescue therapy with levofloxacin is more effective than rifabutin rescue regimen after two Helicobacter pylori treatment failures. Aliment Pharmacol Ther. 2006;24:1469-74.
37.Wei-Chen Tai, Chien-Hua Chiu, Chih-Ming Liang, et al. Ten-Day versus 14-Day Levofloxacin-Containing Triple Therapy for Second-Line Anti-Helicobacter pylori Eradication in Taiwan. Hindawi Publishing Corporation Gastroenterology Research and Practice. Volume 2013, Article ID 932478, 6 pages.
38.Richard J. Saad, Philip Schoenfeld, Hyungjin Myra Kim, and William D. Chey, et al. Levofloxacin-Based Triple Therapy versus Bismuth-Based Quadruple Therapy for Persistent Helicobacter pylori Infection: A Meta-Analysis. Am J Gastroenterol 2006;101:488–496.
Source of support: None
Competing interest / Conflict of interest
The author(s) have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript
Copyright © 2014 Hassan WR, Al-Tukmagi HF, Muslim OT. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Original article
Sireesha Srinivasa Rao1, Srinivas Rao Kuna2, Siva Kumar Chennam Setty3,*
Affiliation:-
1Associate Professor Psychiatry, Institute of mental health (IMH), Hyderabad, Telangana, India
2Civil Surgeon specialist, Department of Orthopedics, ESI Hospital, Sanathnagar, Hyderabad, Telangana, India
3Assistant Professor, Psychiatry, Institute of Mental Health (IMH), Hyderabad, Telangana, India
The name of the department(s) and institution(s) to which the work should be attributed:
1.Psychiatry, Institute of mental health (IMH),Hyderabad, Telangana,India
2.Department of Orthopedics, ESI Hospital, Sanathnagar, Hyderabad, Telangana, India
Address reprint requests to
Sireesha Srinivasa Rao.
Associate Professor Psychiatry, Institute of Mental Health, Yerragadda, Hyderabad, Telangana, India
Article citation:
Rao SS, Kuna SR, Setty SKC. A cross sectional study of psychiatric and physical morbidity among community dwelling urban elderly adults in Hyderabad, India J Pharm Biomed Sci. 2014; 04(11):1014-1024. Available at www.jpbms.info
ABSTRACT
Background and objectives: Age is an important determinant of psychiatric illness. The overall prevalence of mental and behavioural disorders tends to increase with age due to normal ageing of brain, deteriorating physical health and cerebral pathology .Disorders such as depression, anxiety, cognitive and psychotic disorders have a high prevalence among elderly. This study was planned to assess the prevalence and pattern of psychiatric morbidity, medical morbidities, sociodemographic factors associated.
Method: Cross-sectional study where urban elderly subjects were selected by random sampling technique, those who met inclusion criteria were assessed on MMSE,GHQ-30,MINI-plus,GDRS, and Modified Kuppuswamy scale for assessment of socioeconomic status.
Results: The prevalence of psychiatric morbidity amongst urban elderly was found to be 26% ,less in comparison to those reported in earlier studies from India. However the pattern of different disorders was found to be similar. Psychiatric morbidity was found to be more in female gender (76.9%), young old age group (61.52%), literates (84.59%), widowed /unmarried/single (61.52%), middle (38.21%) and low socioeconomic status (38.21%), nuclear families (69.12%). The Current study found statistically a significant association between psychiatric morbidity and age (p value=0.01), literacy (p value=0.02), marital status (p value=0.02), socioeconomic status (p value=0.02) and type of family (p value=0.02). 66.14% of elderly with psychiatric morbidity were found to have hypertension.
Conclusion: Larger studies carried over a longer period of time are recommended for future research. Geriatric clinics will prove helpful in early diagnosis of mental illness.
KEYWORDS: Elderly adults; psychiatric morbidity; physical illness.
REFERENCES
1.Anderson RJ, Freedland KE, Clouse RE, Lustman PJ.2001.The prevalence of comorbid depression in elderly adults with diabetes: a meta analysis. Diabetes Care. 24(6):1069-78.
2.Banker K, Prajapathi B and Kedia G.2011.Study of health profile of residents of geriatric home in Ahmedabad district. National Journal of community Medicine.2:378-82.
3.Banthia JK ,editor.2001.Census of India series I. NewDelhi: Controller of Publications. Appraisal of age data;p99.
4.Barua A, Ghosh MK, Kar N, Basilio MA. Sociodemographic factors of geriatric depression Indian J Psychological medicine. Med know publication obtained from www.science open.com /document vid/ 543be2a2 91d1-443-9315-6 searched on 3.9.2014.
5.Biswas SS, Gupta R, Vanjare HA, Bose S, Patel JA,Selvarajan 2009. Depression in elderly in Vellore, South India: the use of a two question screen. Int Psychogeriatr.21:369-71.
6.Carney RM . 2003. Depression as a risk factor for mortality after acute myocardial infarction. Am J Cardiology. 92(11):1277-81
7.Census of India .2011. Available from: http: //en.Wikipedia.org/wiki 2011 -census of India, Accessed on May 16th, 2014.
8. Chowdhary A,Rasania SK.2008. A community based study of psychiatric disorders among elderly living in Delhi .The Internet Journal of Health.7 (1).
9.Cole MG,Dendukuri N.2004.The feasibility and effectiveness of brief intervention to prevent depression in older subjects : a systemic review. Int J Geriatr Psychiatry.19:1019-25.
10.Desai A, Gross berg G. 2003. Differential diagnosis of psychotic disorders in the elderly: In Cohen CI editor. Schizophrenia in to later life: treatment, research and policy
Washington DC. American Psychiatric publishing, INC p55-78.
11.Folstein MF, Folstein SE, Mc Hugh PR.Mini-Mental status examination (MMSE).1975.A practical method for grading the cognitive state of the patients for the clinicians. J Psychiatr Res.12:189-98.
12.Goldberg DP. 1992.The detection of psychiatric illness by questionnaire. Maudsley monograph 21.London Oxford University press.
13.Jain RK ,Aras RY. 2007.Depression in geriatric population in urban slums in Mumbai. Indian J of Public Health.15:112-3.
14.Joshi K, Kumar R, Avasthi A.2003. Morbidity profile and its relationship with disability and psychological distress among elderly in Northern India. International J Epidemiology.32:978-87.
15.Lesperance F,Frasure-Smith N,Talajic M,Bourassa MG.2002.Five year riskof cardiac mortality in relation to initial severity and one year changes in depression symptoms after MI.Circulation.105(9):1049-53.
16.Levine JB . 1996. Psychological predictors of subsequent medical care among patients admitted with cardiac disease. J Cardio Pulmon Rehabil.16(2):109-16.
17.Mental health and ageing .ICMR bulletin 21;5:49-54.
18.Nandi PS, Banerji G, Mukherjee SP, Nandi S,Nandi DN.1997. A study of Psychiatric morbidity of elderly population of a rural community in West Bengal. Indian J Psychiatry.39:122-9.
19.Park editon.2011. Medicine and Social Sciences.Text book of Preventive and Social Medicine.21st edition: Jabalpur. In: Banarasi Das. Bhanot publishers.p 638-40.
20.Rajan SI .2003.Demography of ageing. In: Dey AB,editor Ageing in India: Situational analysis and planning in future. Ministry of health and family welfare-Govt of India Geneva: WHO.p 3-11.
21.Rajkumar S, Kumar S, Thara R. 1997. Prevalence of dementia in a rural setting: a report from India.Int J Geriatr Psychiatry.12:702-7.
22.Rajkumar AP, Thangadurai P, Senthil Kumar P.2009. Nature and prevalence and factors associated with depression among elderly in a rural south Indian community. International Psycho geriatrics.21:372-8.
23.Ritchie K ,Artero S, Beluche I .2004. Prevalence of DSM -IV Psychiatric disorder in French elderly population. Br J Psychiatry.184:147-52.
24.Seby K, Chaudhary S, Chakraborthy R .2011. Prevalence of psychiatric and Physical morbidity in urban geriatric population. Indian J Psychiatry .53:121-7.
25.Shaji K Arun kishore NR, Lal KP, Pinto C, Trivedi JK.2004. Better mental health care for older people in India. Indian J Psychiatry.46:367-72.
26.Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiler ET.1998 .The Mini-International Neuropsychiatric interview (MINI): The development and validation of a structured diagnostic Psychiatrici interview for DSM-IV and ICD-10 .J Clin Psychiatry.20:22-23.
27.Simonsick EM, Wallace RB, Blazer DG, Berkman LF . 1995. Depressive symptomatology and hypertension-associated morbidity and mortality in older adults. Psychosomatic med.57(5):427-35.
28.Tiwari S, Tripathi R . 2009. Neuropsychiatric morbidity amongst urban and rural elderlies in Northern India: Report from a community based epidemiological study. Int Psychogeriatr. 21(Suppl 2):s136.
29.Tiwari SC.2000. Gero Psychiatric morbidity in rural northern India: Implications for the future. Int Psychogeriatr.12:35-48.
30.Tiwari SC, Srivastava G, Tripathy.2013. Prevalence of psychiatric morbidity amongst the community dwelling rural older adults in North India. Indian J Med Res .138:504-14.
31.Vas CJ,Raj Kumar S, Tanya kitpisal R,Chandra V.2001. Alzheimer's disease: The Brain killer NewDelhi : WHO; p50.
32.Venkoba Rao A, Madhavan T. 1982. GeroPsychiatric morbidity survey in a semiurban area near Madhurai. Indian J Psychiatry. 24:258-62.
33.Yesavage JA, Brink TL, Rose TL, Lum O, Huang V,Adey M. 1983.Development and validation of a geriatric depression rating scale .A preliminary report. J Psychiatr Res.17:37-49.
34.Zayas E, Grossberg T. 1998. The treatment of psychosis in late life. J Clin Psychiatry.59:5-12.
Copyright © 2014 Rao SS, Rao SK, Chennamsetty SK. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Source of support: None
Competing interest / Conflict of interest
The author(s) have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript
Research article
Reyadh Jassim Abbas1,*,May Al- Sabbagh1, Dr Hassan Mohammed Abbas Altemmi2, Dr Monewer3
Affiliation:-
1Department of Clinical Pharmacy, College of Pharmacy, University of Baghdad, Baghdad Iraqi
2Ph.D Clinical Pharmacy, Medical City Baghdad, Baghdad Iraq, 3MSC Oncology Medical City Baghdad, Iraq
The name of the department(s) and institution(s) to which the work should be attributed:
1Department of Clinical Pharmacy, College of Pharmacy, University of Baghdad, Baghdad Iraqi
Address reprint requests to
Reyadh Jassim Abbas
Department of Clinical Pharmacy, College of Pharmacy, University of Baghdad, Baghdad Iraqi
Article citation:
Abbas RJ, Sabbagh-Al M, Altemmi Abaas HM, Monewer. The possible protective effect of melatonin in Iraqi breast cancer patients taking chemotherapy. J Pharm Biomed Sci. 2014; 04(11):1001-1006. Available at www.jpbms.info
ABSTRACT
Breast cancer is the most common cancer that lead to death in the world. The most common type of breast cancer is ductal carcinoma. Chemotherapy that used in the treatment of breast cancer is associated with adverse effects like cardio toxicity, especially with doxorubicin use, due to increase free radical formation like reactive oxygen species. To evaluate the protective effect of melatonin in Iraq breast cancer taking chemotherapy, 40 volunteers, 10 normal subjects served as control, 30 volunteers were divided into two groups randomly first 10 patient named group A taking only chemotherapy without melatonin. The second 20 patient named group B taking melatonin + chemotherapy. In the current study, we measured serum malondialdehyde (MDA), liver function test (ALT, AST and TSB) and cardiac enzyme (CPK and LDH). The results showed that chemo therapy increase serum MDA, AIT, AST, CPK, LDH and reduction in serum TSB. Patients who taking extra supplement with melatonin (group B) showed normalized of these biochemical parameters. Melatonin has a role in protecting against toxicity that produced by chemotherapy.
KEYWORDS: Breast cancer; Chemotherapy; melatonin.
REFERENCES
1.American cancer society . Breast cancer . Fact and Figure 2009. American cancer society, Atlanta, GA2009.
2.Iraq cancer registry, 2010,p28.
3.Wood, WC et at. Malignant tumor of breast in ;devitant,Hellman editor.Cancer principle and practice of oncology 7th edition , Philadelphia Pa. Lippincott william and Wilkins, pp77-1415.
4.Chu, E et al . Cancer chemotherapy.In; Katzung BG,editor. Basic and clinical pharmacology, 9th edition . Mc Graw-Hill, pp: 898-930.
5.Stefulj J et al. Gene expression of the key enzymes of melatonin synthesis in extrapineal tissues of the rat. J Pineal Res. 2001;30:243–247.
6.Ackermann K et al. Melatonin synthesis in the human pineal gland .BMC neuroscience. 2007; 8supp1:p2.
7.Pieri C. Melatonin peroxyl radical scavenger more effective than vit. E Life sci. 55(15): PL 271-6.
8.Reitman and frankel. As cited by Bio Merieux kit (france). Am J Clin Path.1957;28:56 .
9.Tietz N.W. text book of clinical chemistry 3rd ed. (1999):1133-1137.
10.Buege, JA, Austa SD. Method enzymol. 1978;51:302-310.
11.Sharhar S. et al. Antioxidant intake and status, and oxidative stress in relation to breast cancer risk: A case-control study. Asian Pac. J. Cancer Prev. 2008;9:343–349.
12.Wiseman H, Halliwell B. Damage to DNA by reactive oxygen and nitrogen species: role in inflammatory disease and progression to cancer. Biochem J. 1996;313:17-29.
13.A.Nath et al. Elevated lipid peroxidation in breast cancer patients, Journal of pharmacy and biological sciences (JPBS),2001;9(4):17-21.
14.Shaoyu Zhou,et al. Doxorubicin–induce persistent oxidative stress to cardiac myocytes.2001;121:(3):151-157.
15.Ganiyu Oboh et al . Cyclophosphamide- induced oxidative stress in brain. Experimental and Toxicologic Pathology.2014;66(8):351-406.
16.Satoshi Numazawa et al. Possible Involvement of Oxidative Stress in 5-Fluorouracil-Mediated myelosuppression in mice. Basic & Clinical Pharmacology & Toxicology.2011;108(1):40–45.
17.Qi W, Reiter RJ, Tan DX, et al. Inhibitory effects of melatonin on ferric nitrilotriacetate-induced lipid peroxidation and oxidative DNAdamage in the rat kidney. Toxicology.1999;139:81–91.
18.Bateman JR, et al. 5-Fluorouracil given once weekly: comparison of intravenous and oral administration. Cancer. 1971;28:907-913.6
19.Paul D. King et al.Hepatotoxicity of Chemotherapy, The Oncologist.2001;6:162-176.p163.
20.Meredith MJ, Reed DJ. Depletion in vitro of mitochondrial glutathione in rat hepatocytes and enhancement of lipid peroxidation by Adriamycin and 1,3 chloroethyl-nitrosurea (BCNU). Biochem Pharmacol 1983;32:1383-1388.
21.Deepa PR, Varalakshmi P. Protective effect of low molecular weight heparin on oxidative injury and cellular abnormalities in adriamycin-induced cardiac and hepatic toxicity. Chemico-Biological Interactions. 2003;146:201-210.
22.Dr. Mustafa Ghazi Alabbassi. Melatonin Ameliorates Hepatic Damage Induced by Cyclophosphamide in rat.
23.Bahir Abdul Razzaq Mshemish et al . Effect of Silymarin against CAF protocol Hepatotoxicity, AJPS, 2011, Vol. 9, No.1.
24.Khalid A Al-Khazragi FRCP. Studying the Effect of Silymarin Against Hepatotoxicity Induced by CAF Protocol in Breast Cancer Women. Iraqi Medical Journal , Volume 56, Number 2, December 2010, ISSN 0304-4564.
25.Kamal Adel Amin,et al . Impact of Breast Cancer and Combination Chemotherapy on Oxidative Stress, Hepatic and Cardiac Markers, Sep 2012:15(3);306-312.
26.Ayça Bilginoğlu, M.D et al. Protective effect of melatonin on adriamycin-induced cardiotoxicity in rats. Arch Turk Soc Cardiol 2014; 42(3):265-273.
27.Pai VB, Nahata MC. Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. http://www.nlm.nih.gov. Drug Saf. 2000 Apr;22(4):263-170.
Source of support: None
Competing interest / Conflict of interest
The author(s) have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Copyright © 2014 Abbas RJ, Sabbagh-Al M, Altemmi Abaas HM, Monewer. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Research article
Babafemi, E. O.1, David, O. M.1, Oluduro, A. O.2 and Famurewa, O.1,*
Affiliation:-
1Department of Microbiology University of Ado-Ekiti, Nigeria.P.M.B.5363, Ado-Ekiti, Nigeria.
2Department of Microbiology, ObafemiAwolowo University, Ile-Ife, Nigeria
The name of the department(s) and institution(s) to which the work should be attributed:
Department of Microbiology, Ekiti State University, Ado-Ekiti, Nigeria, P.M.B. 5363, Ado-Ekiti, Nigeria
Department of Microbiology, Obafemi Awolowo University, Ile-Ife, Nigeria
Address reprint requests to
Famurewa, O.
Department of Microbiology Ekiti State University, Ado-Ekiti, Nigeria P.M.B. 5363, Ado-Ekiti, Nigeria
Article citation: Babafemi EO, David OM, Oluduro AO, Famurewa O. Epidemiology of methicillin-resistant Staphylococcus aureus among hospitalized patients and apparently healthy individuals in Ekiti and Ondo States, Nigeria. J Pharm Biomed Sci. 2014; 04(11):1025-1030. Available at www.jpbms.info
ABSTRACT
The incidence of methicillin-resistant Staphylococcus aureus (MRSA) in hospitalized patients and apparently healthy individuals was investigated in two western states of Nigeria using standard microbiological methods. One thousand and two hundred non-repeat isolates of S. aureus were recovered from the subjects. At varying degrees the isolates were resistant to cotrimoxazole (54.8%), augmentin (36.9%), pefloxacin (35.9%), gentamycin (28.3%), erythromycin (24.9%), vancomycin (10.3%), ofloxacin (5.2%) and ciprofloxacin (0.3%). One hundred and fifty six (13.0%) were resistant to methicillin out of which 4.8% and 8.2% were from healthy individuals and patients respectively. There was no correlation between prevalence of MRSA and age or sex (p < 0.05). There was no correlation between the antibiotic resistance pattern in MRSA from healthy volunteers and patients (P < 0.05). A total of 9.0%, 12.2% and 21.2% of the MRSA were resistant to 3, 4 and 5 antibiotics respectively. Antibacterial activities of five biocides examined using agar diffusion method showed that 38.5%, 53.2%, 59.6%, 61.5% and 71.8% of the MRSA were not inhibited by Izal®, Morigad®, Septol®, Dettol® and Purit® respectively, at concentrations two times higher than the in-use concentration. This finding points to the fact that MRSA occurs among patients and in the communities in the study areas, which calls for a public health concern and awareness.
KEYWORDS: Hospital-acquired MRSA; community acquired MRSA; biocides, epidemiology; multiple antibiotic resistance.
REFERENCES
1.Abraham B, Jacob G, Pablo Y, Nechawa P, Nurith P, Ronif T, Hannah S, Klaris R, Miriam S, Francis S. Community acquired MRSA in institutionalized adults with development disabilities. Emerg Infect Dis. 2002; 8:966-969.
2.Adeleke SI, Asani MO. Urinary tract infection with children with nephritic syndrome in Kano, Nigeria. Ann Afr Med. 2009; 8:38-41.
3.Ahmed MO, Elramalli AK, Amri SG, Abuzweda AR, Abouzeed YM. Isolation and screening of methicillin-resistant Staphylococcus aureus from health workers in Libyan hospitals. East Meditrr Health J. 2012; 18(1):37-42.
4.Ako-Nai AK, Ogunniyi AD, Lamikanra A, Torimiro SE. The characterisation of clinical isolates of Staphylococcus aureus in Ile-Ife, Nigeria. J Med Microbiol. 1991; 34:109-112.
5.Akujobi CN, Ilo IA, Egwuatu CC, Ezeanya CC. Prevalence of methicillin-resistant Staphylococcus aureus (MRSA) among healthcare workers in a tertiary institution in Nigeria. Orient J Med. 2013; 25(3-4):82-87.
6.Anyanwu NCJ, Abdullahi IO, Ameh JB, Ella EE. Molecular detection of PVL, msrA genes and antibiotic susceptibility pattern of staphylococcus aureus from skin and soft tissue infections in Zaria, Nigeria. Scient J Microbiol. 2013: 2(2):43-52.
7.Ateba NU, Schaumburg F, Adegnika AA, Kosters K, Möller T, Fernandes JF, Alabi A, Issifou S, Becker K, Grobusch MP, Kremsner PG, Lell B. Epidemiology and population structure of Staphylococcus aureus in various population groups from a rural and semi urban area in Gabon, Central Africa. Acta Trop. 2012; 124:42-47.
8.Boyce JM. MRSA in hospitals and long term care facilities: microbiology, epidemiology and preventive measures. Infect Contr Hos Epidemiol. 2005; 13:725-734.
9.Castillo JA, Clapes P, Infante MR, Comas J, Manresa A. Comparative study of the antimicrobial activity of bis-(N{alpha}-caproyl-L-arginine)-1,3-propanediamine dihydrochloride and chlorhexidinedihydrochloride against Staphylococcus aureus and Escherichia coli. J Antimicrob Chemother. 2006; 57:691-698.
10.Choi SC, Chow SY, Afra A. Nasal carriage of Staphylococcus aureus among healthy adults. J Microbiol Immunal Infect. 2006; 39:458-464.
11.Chopra I. Bacterial resistance to disinfectants, antiseptics and toxic metal ions. Soc Appl Bacteriol Tech Ser. 1991; 27:45-64.
12.CLSI. Performance Standards for Antimicrobial Disk Susceptibility Tests; Approved Standard—Eleventh Edition. M02-A11 32(1) Replaces M02-A10. 2012; 29(1).
13.Craig EZ, Bryon C, Mark AM, James EL, Adam A, Bruce KB. Community-acquired methicillin-resistant Staphylococcus aureus among Military Recruits. Emerg Infect Dis. 2004; 10:941-943.
14.David OM, Fakayode IB, Famurewa O. Evaluation of the anti-enterococcal activity of disinfectants and medicated soaps on vancomycin-resistant Enterococcus faecalis strains. Ann Res Rev Biol. 2014; 4(3):509-519.
15.David OM, Ayeni D, Fakayode IB, Famurewa O. Evaluation of antibacterial properties of various hand sanitizers wipes used for cosmetic and hand hygiene purposes in Nigeria. Microbiol Res Inter. 2013; 1(2): 22-26.
16.El-Mahmood AM, Doughari JH. Bacteriological examination of some diluted disinfectants routinely used in the Specialist Hospital Yola, Nigeria. Afr. J. Pharm Pharmacol. 2009; 3:185-1909.
17.Esan CO. Molecular studies of resistant Staphylococcus aureus in Ekiti and Ondo States, Nigeria. Ph.D Thesis. University of Ado-Ekiti, Nigeria. 2011.
18.Fawole MO, Oso BA. Laboratory Manual of Microbiology. Spectrum Books Limited, Ibadan. 2001; 127.
19.Fayyaz M, Mirza IA, Ahmed Z, Abbasi SA, Hussain A and Ali S. (). In vitro susceptibility of chloramphenicol against methicillin-resistant Staphylococcus aureus. J Coll Physic Surg Pak. 2013; 23(9): 637-640.
20.Fraise AP. Biocide abuse and antimicrobial resistance – A cause for concern? J Antimicrob Chemother. 2002; 49:1-12
21.Ghebremedhin B, Olugbosi MO, Raji AM, Layer F, Bakare RA, Konig B, Konig W. Emergence of a community-associated methicillin-resistant Staphylococcus aureus with unique resistance profile in Southwest of Nigeria. J Clin Microbiol. 2009; 47: 2975-2980.
22.Gilbert P, McBain AJ. Potential impact of increased use of biocides in consumer products on prevalence of antibiotic resistance. Clin Microbiol Rev. 2003; 16:189-208.
23.Holt JG, NR Krieg, PHA Sneath, JT Staley, and ST Williams. Bergey’s Manual of Determinative Bacteriology, 9th Edn. Williams & Wilkins, Baltimore. 1994.
24.Karpanen TJ, Worthington T, Hendry ER, Conway BR, Lambert PA. Antimicrobial efficacy of chlorhexidine digluconate alone and in combination with eucalyptus oil, tea tree oil and thymol against planktonic and biofilm cultures of Staphylococcus epidermidis. J Antimicrob Chemother. 2008; 325:1-6.
25.Kejela T, Bacha K. Prevalence and antibiotic susceptibility pattern of methicillin-resistant Staphylococcus aureus (MRSA) among primary school children and prisoners in Jimma Town, Southwest Ethiopia. Ann Clin Microbiol Antimicrob. 2013: 24: 12:11
26.Kesah C, Redjeb S.B., Odugbemi T.O., Boye C.S-B., Dosso M., NdinyaAchola J.O., Koulla-Shiro S, Benbachir M., Rahal K., Borg M (2003). Prevalence of methicillin-resistant Staphylococcus aureus in eight African hospitals and Malta. Clin.Microbiol. Infect. 9:153-156.
27.Kluytmans J, van Belkum A, Verbrugh H (1997). Nasal carriage of Staphylococcus aureus: epidemiology, underlying mechanisms, and associated risks. Clin Microbiol Rev. 10 (3): 505–20.
28.Kolman1, S, Arielly H, Paitan Y. Evaluation of single and double-locus real-time PCR assays for methicillin-resistant Staphylococcus aureus (MRSA) surveillance. BMC Res Notes. 2010; 3:110
29.Kumurya AS. Loss of the mecA gene during storage of methicillin-resistant Staphylococcus aureus isolates in Northwestern Nigeria. J Public Health Epidemiol. 2013; 5(10):410-415.
30.Little-John TG, Paulsen IT, Gillespie MT, Tennent JM, Midgley M, Jones IG. Substrate specificity and energetic of antiseptic and disinfectant resistance in Staphylococcus aureus. FEMS Letters. 1992; 95:259-266.
31.Monecke S, Ruppelt A, Wendlandt S, Schwarz S, Slickers P, Ehricht R, Jäckel SC. Genotyping of Staphylococcus aureus isolates from diseased poultry. Vet Microbiol. 2013; 162: 806-812.
32.Nadjia B, Mebrouk K. Phenotypic and genotypic characterization of Staphylococcus aureus agents of dairy cows’ mastitis in Algeria. J Appl Sci Res. 2013; 9(1):86-93.
33.Noguchi N, Nakaminami H, Nishijima S, Kurokawa I, So H, Sasatsu M. Antimicrobial agent of susceptibilities and antiseptic resistance gene distribution among methicillin-resistant Staphylococcus aureus isolates from patients with impetigo and staphylococcal scalded skin syndrome. J Clin Microbiol. 44: 2119-2125.
34.Noguchi N, Suwa J, Narui K, Sasatsu M, Ito T, Hiramatsu K, Song JH. Susceptibilities to antiseptic agents and distribution of antiseptic-resistance genes qacA/B and smr of methicillin-resistant Staphylococcus aureus isolated in Asia during 1998 and 1999. J Med Microbiol. 2005; 54:557-565.
35.Nwakwo BOK, Abdulhadi S, Magagi A, Ihesiulor G. Methicillin resistant Staphylococcus aureus and their antibiotic susceptibility pattern in Kano, Nigeria. Afr J Clin Experim.Microbiol. 2010; 11(1):1595-689.
36.Ebrahimi A, Ghasemi M, Ghasemi B. Some Virulence Factors of Staphylococci Isolated From Wound and Skin Infections in Shahrekord, IR Iran. Jundishapur J Microbiol. 2014; 7(4):1-5.
37.Obajuluwa AF, Onaolapo JA, Oyi AR, Olayinka BO. Susceptibility profile of methicillin-resistant Staphylococcus aureus (MRSA) Isolates to antibiotics and methanolic extracts of parkia biglobosa (Jacq) Benth. Brit J Pharma Res. 2013; 3(4):587-596.
38.Odetoyin WB, Aboderin AO, Ikem RT, Kolawole BA, Oyelese AO. Asymptomatic bacteriuria in patients with diabetes mellitus in Ile-Ife, South-West, Nigeria. East Afr Med J. 2008; 85:18-23.
39.Olutiola PO, Famurewa O, Sonntag H-G. An Introduction to General Microbiology.Hygiene-Institut Der Universitat Heidelberg Federal Republic of Germany. 2001; 267.
40.Onemu OS, Ophori EA. Prevalence of multi-drug resistant Staphylococcus aureus in clinical specimens obtained from patients attending the University of Benin Teaching Hospital, Benin City, Nigeria. J Nat Sci Res. 2013; 3(5):154-159.
41.Onochie CC, Chukwudi A, Alo MN, Onwa NC, Okonkwo EC and Afiukwa FN. Bacteriological examination of computer keyboards and mouse devices and their susceptibility patterns to disinfectants. Amer J Microbiol. 2013; 4(1):9-19.
42.Pallin DJ, Egan DJ, Pelletier AJ, Espinola JA, Hooper DC, Camargo CA. Increased US Emergency Department visits for skin and soft tissue infections, and changes in antibiotic choices, during the emergence of community-associated methicillin- resistant Staphylococcus aureus. Ann Emerg Med. 2008; 51:291-298.
43.Popovich KJ, Weinstein RA, Hota B. Are community-associated methicillin- resistant Staphylococcus aureus (MRSA) strains replacing traditional nosocomial MRSA strains? Clin Infect Dis. 2008; 46:787-794.
44.Price CS, Williams A, Philips G, Dayton M, Smith W, Morgan S. Staphylococcus aureus nasal colonization in pre-operative orthopaedic out patients. Clin Orthop Relat Res. 2008; 466:2824-2847.
45.Ramdani-Bouguessa N, Bes M, Meugnier H, Forey F, Reverdy ME, Lina G, Vandenesch F, Tazir M, Etienne J. Detection of methicillin-resistant Staphylococcus aureus strains resistant to multiple antibiotics and carrying the Panton-Valentine leukocidin genes in an Algiers hospital. Antimicrob Agents Chemother. 2006; 50:1083-1085.
46.Sheikh AF, Mehdinejad M. Identification and determination of coagulase-negative Staphylococcus species and antimicrobial susceptibility pattern of isolates from clinical specimens. Afri J Microbiol Res. 2012; 6(8):1669-1674.
47.Shittu AO, Lin J, Kolawole DO. Antimicrobial susceptibility patterns of Staphylococcus aureus and characterization of MRSA in Southwestern Nigeria. Wounds. 2006; 18:77-84
48.Shittu AO, Lin J. Antimicrobial susceptibility pattern and characterization of clinical isolates of Staphylococcus aureus in Kwazulu-Natal province of South Africa. BMC Infect Dis 2006; 6:188-192.
49.Smith TL, Pearson ML, Wilcox KR. Emergence of Vancomycin resistance in Staphylococcus aureus. NEJM. 1999; 340:493-501.
50.Tula MY, Azih AV, Okojie RO. Antimicrobial susceptibility pattern and plasmid-mediated antibacterial resistance in Staphylococcus aureus and coagulase-negative staphylococci (CoNS). Amer J Res Com. 2013; 1(9):149-166.
51.Weber DJ, Rutala WA, Sickbert-Bennett EE. Outbreaks associated with contaminated antiseptics and disinfectants. Antimicrob Agents Chemother. 2007; 51:4217-4224.
Source of support: None
Competing interest / Conflict of interest
The author(s) have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Copyright © Babafemi EO, David OM, Oluduro AO, Famurewa O. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Case report
Shiddalingesh Salimath* Janaki Torvi. R., S G S Rajesh Reddy .V.
Affiliation:-
Department of Pharmacology, Karnataka Institute of Medical Sciences, Hubli, Karnataka, India
The name of the department(s) and institution(s) to which the work should be attributed:
Department of Pharmacology, Karnataka Institute of Medical Sciences, Hubli, Karnataka, India
Address reprint requests to
Dr.Shiddalingesh Salimath.
Department of Pharmacology, Karnataka Institute of Medical Sciences, Hubli, Karnataka, India
Article citation: Salimath S, Torvi. RJ, Reddy SGS Rajesh V. Doxycycline Induced fixed drug eruption. J Pharm Biomed Sci. 2014; 04(11):1011-1013. Available at www.jpbms.info
ABSTRACT
Fixed drug eruption (FDE) represents the most common cutaneous adverse drug reaction in Indian patients, accounting for 30% of all cutaneous adverse drug reactions. More than 100 drugs, including Doxycycline have been implicated in causing FDEs. The most common drugs causing FDE are Antibiotics (trimethoprim sulfamethoxazole, tetracycline, penicillin, and erythromycin), followed by Nonsteroidal Anti-Inflammatory Drugs (NSAIDs; Diclofenac Sodium, Aspirin, Naproxen, and Ibuprofen). One large study of 450 patients revealed male to female ratio for FDE is 1:1.1. This is a case of 29year old male patient presenting to skin OPD with complaints of erythematous skin rashes associated with burning & itching sensation. The patient stated that these lesions had appeared within a few hours of taking a single dose of oral Doxycycline 500mg for a hordeolum externum. A diagnosis of FDE to Doxycycline was made and the patient was told to stop the offending agent and was started on oral antihistamines (Tab cetrizine) and topical steroid cream (mometasone). FDE from doxycycline is a rare occurrence. When it does occur, it is often misdiagnosed. Physicians should be aware of this condition in order to prevent future recurrences as it causes a lot of cosmetic and physical discomfort to the patient.
KEYWORDS: Fixed drug eruption; doxycycline.
REFERENCES
1.Patel RM, Marfatia YS. Clinical study of cutaneous drug eruptions in 200 patients. Indian J Dermatol Venerol Leprol.2008;74:430.
2.Lee AY. Fixed drug eruptions. Incidence, recognition, and avoid¬ance. Am J Clin Dermatol. 2000; 1:277-85.
3.Breathnach SM. Drug reactions.In:Burns T, Breathnach S, Cox N, Griffi ths C,editors.Rook’s Textbook of Dermatology. 8th ed.,Oxford: Blackwell Science; 2010.p.28-177.
4.Mahaboob A, Haroon TS, Drugs causing fixed drug eruptions: a study of 450 cases. Int J Dermatol. Nov 1998;37(11):833-8.
5.MacDougall C, Chambers HF. Protein synthesis inhibitors and miscellaneous antibacterial agents. In:Brunton LL, Chabner BA, Knollmann BC,editors.Goodman & gilman's the pharmacological basis of therapeutics.12thed.New York: Mcgraw-Hill; 2006 .p.1521-1526. 6.Pai VV, Bhandri P, Kikkeri NN, Athanikar SB, Sori T. Fixed drug eruption to fluconazole: a case report and review of literature.Indian J Pharmacol.2012;44:643-5.
7.Malkarnekar SB, Naveen L. Fixed drug eruption due to clarithromycin. J Res Pharm Pract. 2013;2:169-171.
8.Lim WS, Kim DH, Jin SY, Choi YS, Lee SH, Huh HJ, et al. A case of fixed drug eruption due to doxycycline and erythromycin present in food.Allergy Immunol Res 2013;5(5):337-339.
Source of support: None
Competing interest / Conflict of interest
The author(s) have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Copyright © Salimath S,cTorvi. RJ, Reddy SGS Rajesh V. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.